Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,632 signal articles · 27 in last 24h · 155,721 total before filter · latest 3h ago
27last 24h
848last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings106M&A122Regulatory20Product21Analyst19
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Atlassian (TEAM) Wins RBC Backing, Is The Valuation Already Too Rich?
Simply Wall St.26d agobullish
Atlassian (TEAM) Wins RBC Backing, Is The Valuation Already Too Rich?

RBC coverage initiation puts Atlassian in focus RBC Capital’s initiation of coverage on Atlassian (NasdaqGS:TEAM) with an Outperform rating has drawn fresh attention to the stock, following a recent 52 week high and a quarterly earnings update. Atlassian’s recent rally has been sharp, with a 1 month share price return of 88.5% and a 90 day share price return of 74.53%. This has helped it reach a 1 year total shareholder return of 7.11%, despite a 5 year total shareholder return that is down...

The Stock Market Rally Is About to Face Its Biggest Test
Barrons.com26d agobullish
The Stock Market Rally Is About to Face Its Biggest Test

The new month, historically the worst for the stock market, hasn’t quite started yet but it’s already looking like being fraught with risk. The market is getting more confident that the Federal Reserve will hike interest rates on Sept. 16, even if Federal Reserve Chairman Kevin Warsh didn’t quite say as much in his Jackson Hole speech Friday. Oil prices aren’t helping, rising above $90 a barrel after the U.S. attacked Iran over the weekend.

Investing.com26d agobullish
Jefferies starts biopharma firm Braveheart at Buy after IPO

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

Why CrowdStrike Holdings (CRWD) Is Up 14.5% After Raising Guidance And Expanding AI Security Partnerships - And What's Next
Simply Wall St.26d agobullish
Why CrowdStrike Holdings (CRWD) Is Up 14.5% After Raising Guidance And Expanding AI Security Partnerships - And What's Next

CrowdStrike Holdings recently reported past second-quarter results showing revenue rising to US$1,470.9 million and moving from a net loss to a modest net profit, while also lifting its full-year revenue guidance and issuing higher forecasts for the coming quarter. At the same time, new integrations with partners like Theta Lake and Endace are expanding Falcon Next-Gen SIEM’s role at the center of AI-focused and network-deep security operations, reinforcing CrowdStrike’s positioning in...